1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > R-Pharm - Product Pipeline Review - 2014

R-Pharm - Product Pipeline Review - 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 28 pages

R-Pharm - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘R-Pharm - Product Pipeline Review - 2014’, provides an overview of the R-Pharm’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of R-Pharm’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of R-Pharm including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of R-Pharm’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the R-Pharm’s pipeline products

Reasons to buy

- Evaluate R-Pharm’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of R-Pharm in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the R-Pharm’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of R-Pharm and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of R-Pharm
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of R-Pharm and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

R-Pharm - Product Pipeline Review - 2014
Table of Contents

R-Pharm Snapshot 4
R-Pharm Overview 4
Key Information 4
Key Facts 4
R-Pharm - Research and Development Overview 5
Key Therapeutic Areas 5
R-Pharm - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
R-Pharm - Pipeline Products Glance 11
R-Pharm - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
R-Pharm - Drug Profiles 13
cefilavancin 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
narlaprevir 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
olokizumab 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
RPH-203 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
R-Pharm - Pipeline Analysis 19
R-Pharm - Pipeline Products by Target 19
R-Pharm - Pipeline Products by Route of Administration 20
R-Pharm - Pipeline Products by Molecule Type 21
R-Pharm - Pipeline Products by Mechanism of Action 22
R-Pharm - Recent Pipeline Updates 23
R-Pharm - Dormant Projects 25
R-Pharm - Locations And Subsidiaries 26
Head Office 26
Other Locations and Subsidiaries 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28

List of Tables

R-Pharm, Key Information 4
R-Pharm, Key Facts 4
R-Pharm - Pipeline by Indication, 2014 6
R-Pharm - Pipeline by Stage of Development, 2014 7
R-Pharm - Monotherapy Products in Pipeline, 2014 8
R-Pharm - Partnered Products in Pipeline, 2014 9
R-Pharm - Partnered Products/ Combination Treatment Modalities, 2014 10
R-Pharm - Phase II, 2014 11
R-Pharm - Phase I, 2014 12
R-Pharm - Pipeline by Target, 2014 19
R-Pharm - Pipeline by Route of Administration, 2014 20
R-Pharm - Pipeline by Molecule Type, 2014 21
R-Pharm - Pipeline Products by Mechanism of Action, 2014 22
R-Pharm - Recent Pipeline Updates, 2014 23
R-Pharm - Dormant Developmental Projects,2014 25
R-Pharm, Other Locations 26
R-Pharm, Subsidiaries 26

List of Figures

R-Pharm - Pipeline by Top 10 Indication, 2014 6
R-Pharm - Pipeline by Stage of Development, 2014 7
R-Pharm - Monotherapy Products in Pipeline, 2014 8
R-Pharm - Partnered Products in Pipeline, 2014 9
R-Pharm - Pipeline by Top 10 Target, 2014 19
R-Pharm - Pipeline by Top 10 Route of Administration, 2014 20
R-Pharm - Pipeline by Top 10 Molecule Type, 2014 21
R-Pharm - Pipeline Products by Top 10 Mechanism of Action, 2014 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.